Print Icon

Next Generation Proteomics Highlights

Dear Subscriber, 

We are excited to share the latest updates and news from and around Biognosys and our research services with you:

Biognosys Expands Its Global Presence with a US Office in Cambridge

Biognosys is excited to announce its further expansion into North America. To complement our expanding Business Development and Scientific teams located in the US, we have opened an office in the hub of pharma and biotech in Cambridge, MA. Stay tuned for our ribbon cutting later this year!

Meet Us at ASMS ’22 and Follow our Presentations and Seminars

We are at ASMS at booth #306. Biognosys is proud of its extensive scientific presence: highlights include the launch of Spectronaut 16, which has undergone one of its most transformative upgrades to date, and innovative studies performed with Biognosys’ proprietary TrueTarget™ and TrueDiscovery™ proteomics platforms for drug and biomarker discovery.

How to Accelerate and De-risk Drug Development in Oncology

In this white paper, you can learn about the key reasons oncology drug development fails and how Biognosys’ proteomics platforms can support your oncology research pipeline. We collected case studies on the most groundbreaking research advancements from our scientific collaborations and peer-reviewed publications.

Discovery of MHC Class I and II Neoantigens in Lung Cancer

Discover a newly emerging game-changer proteomics approach in this Resyn Biosciences’ webinar featuring our Principal Scientist! Learn more about our immunopeptidome profiling service to robustly identify immunopeptides from low amounts of cultured cells and tissue samples and its application in a recent study on lung cancer.

Visit our website to learn more about how we can support your proteomics research, and subscribe to our Proteomics Highlights to stay up to date with the latest news:

Best regards, 
The Biognosys Team

Can't read or view images? View in Browser

Not interested? Unsubscribe

No more? Opt Out from Organization